91 results on '"Treacy, Daniel"'
Search Results
2. Data from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
3. Supplementary Methods, Tables 1 - 9, Figures 1 - 8 from Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
4. Supplementary Table 3 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
5. Data from Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
6. Supplementary Table 2 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
7. Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
8. Supplementary Table S2 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
9. Data from Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
10. Supplementary Table S5 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
11. Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
12. Supplementary Table 4 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
13. Supplementary Table 1 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
14. Data from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
15. Supplementary Table 6 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
16. Supplementary Table 6 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
17. Supplementary Figures from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
18. Supplementary Table S3 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
19. Supplementary Table S1 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
20. Supplementary Figures from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
21. Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
22. Supplementary Table 1 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
23. Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
24. Supplementary Table S2 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
25. Supplementary Table 2 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
26. Supplementary Table S1 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
27. Supplementary Table S5 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
28. Supplementary Table 3 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
29. Data Supplement from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
30. Supplementary Table S3 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
31. Supplementary Table 4 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
32. Supplementary Table 5 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
33. Supplementary Table 5 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
34. Supplementary Methods, Tables 1 - 9, Figures 1 - 8 from Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
35. Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
36. Data Supplement from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
37. Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
38. Mobility and Frailty Rehabilitation in Older Adults
39. Supplementary Table 3 from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
40. Data from ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
41. Suppl Figure 3 from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
42. Data from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
43. Data from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
44. Suppl Figure 4 from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
45. Supplementary Table 1 from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
46. Supplemental Figures 1-8 from ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
47. Supplementary Information from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
48. Suppl Figure 1 from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
49. Data from ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
50. Supplementary Table 2 from PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.